Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

eas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement may contain, in addition to historical information, certain forward-looking statements regarding motavizumab, an investigational MAb, which involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission. The company is developing motavizumab for potential future marketing. There can be no assurance that such development efforts will succeed, that motavizumab will receive required regulatory approval or that, even if such regulatory approval is received, that motavizumab would ultimately achieve commercial success.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important informat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... that it has received final approval for its common shares ... Exchange (the "TSX"). The Company,s common shares will commence trading ... under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares will ... About ESSA Pharma Inc. ESSA Pharma is a ...
(Date:7/28/2015)... 2015 According to a new market ... Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration ... to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery ... $114.7 Billion in 2015, growing at a CAGR of 12.6% ... 230 market data T ables and ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Fertility specialist ... as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors ... hundreds of her esteemed colleagues and peers in the metro area as one of ...
(Date:7/28/2015)... ... 28, 2015 , ... A new study published by HealthDay News on June ... light on a possible new treatment option for people living with fibromyalgia – hyperbaric ... at least five per week, patients experienced a significant decrease in pain, fatigue, and ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... lead to cognitive problems , , FRIDAY, Dec. 19 (HealthDay ... matter in a fetus, frontal and occipital lobes, which ... processing. The finding may help explain problems seen in ... says. , "The brain,s white matter is made up ...
... ultrasound device, developed by a Cornell graduate student, fits in ... punch to stabilize a gunshot wound or deliver drugs to ... called a transducer, and it creates sound waves so strong ... steam., Tinkering in his Olin Hall lab, George K. Lewis, ...
... hold the secret to eradicating malaria or schistosomiasis? ... is utilizing the combination of algorithms and models ... in the fight against infectious diseases. , Professor ... and analyze symptoms, treatment outcomes and environmental conditions ...
... with thoughts of getting in shape and improving our health, yet without ... fall by the wayside rather quickly. With a team approach, the ... tips to ensure success for a new and improved you in the ... ...
... program during holidays and economic challenges , ... ... provider of medical information and retail products understands the tough ... said "with the economy in shambles and millions of people ...
... the largest grant in its history: $24.4 million from ... cultural disparities in oral health. , The seven-year ... of Dental and Craniofacial Research, will enable the UCSF ... CAN DO) to launch new programs in preventing early ...
Cached Medicine News:Health News:Moms-to-Be Who Drink May Damage Fetus' White Matter 2Health News:Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 3Health News:Case Western Reserve professor helps control infectious diseases with models and math 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 2Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 3Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 5Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 6Health News:UCSF receives $24.4 million to fight early childhood cavities 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: